Recently, Jänne et al. published the results from cohort A of the phase I/II KRYSTAL-1 trial with single agent adagrasib in previously treated patients with KRAS G12C-mutated NSCLC [78]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.